Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376172 | 1.00 | PDE4B (0.56) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL28542087 | 1.00 | PDE4B (0.56) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL20121078 | 1.00 | PDE4B (0.56) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL13315211 | 0.92 | PDE4B (0.54) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL19918950 | 0.92 | PDE4B (0.54) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL3388396 | 0.92 | PDE4B (0.54) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL1355893 | 0.92 | PDE4B (0.54) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL3388401 | 0.92 | PDE4B (0.54) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL30060223 | 0.91 | PDE4B (0.59) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL7498881 | 0.91 | PDE4B (0.59) | PDE4BSMN1; SMN2NPC1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-3885342-B1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-4267587-A2 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | Gilead Sciences, Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-4143189-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| CN-115551862-A | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-109069869-B | Bicyclic PAD4 inhibitors | 帕德罗科治疗公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20220227787-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. | 2022-07-21 | — | — | US | disclosed |
| WO-2022140428-A2 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | PDE4B 61/4885SMN1; SMN2 2054/4885NPC1 3253/4885 |
| US-20220227787-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | PADI4, PADI2, PADI1 | PDE4B 43/4885SMN1; SMN2 3144/4885NPC1 3533/4885 |
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | PADI4, PADI2, PADI1 | PDE4B 61/4885SMN1; SMN2 2054/4885NPC1 3253/4885 |
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | PDE4B 61/4885SMN1; SMN2 2054/4885NPC1 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.